Multimodal Ultrasonographic Analysis of HER-2 Positive Breast Cancer Patients with Different Expression States of Estrogen Receptor and Progesterone Receptor
JI Liping, XING Guochen, FENG Peibei, et al
Department of Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou Henan 450007
Abstract：【Objective】To investigate the multimodal ultrasound characteristics of human epidermal growth factor receptor 2 (HER-2) positive breast cancer patients with different expression states of estrogen receptor (ER) and progesterone receptor (PR). 【Methods】A total of 149 patients with HER-2 positive breast cancer admitted to our hospital from May 2020 to March 2024 were selected and divided into group A (n=71, positive HER-2, negative ER and PR), group B (n=27, positive HER-2, positive ER or PR) and group C (n=51, positive ER or PR) according to immunohistochemical results. HER-2, ER, PR positive).Ultrasonic characteristics of HER-2 positive breast cancer patients with different expression states of ER and PR were analyzed. 【Results】The proportion of the group A with unclear boundary, enhanced posterior echo, calcification, mixed internal echo, aspect ratio > 0.7, Adler grade 2-3, and BI-RADS grade 5 was higher than that of the group B and the group C (P<0.05). The above indexes in the group B were higher than those in the group C (P<0.05). The ratio of elasticity score ≥3 and hardness ratio of lesion tissue to adipose tissue in the group A were higher than those in the groups B and C (P<0.05).The above indexes in group B were higher than those in the group C (P<0.05). The peak time (PT) in the group A was shorter than that in the groups B and C (P<0.05), and the PT in group B was shorter than that the in group C (P<0.05). The proportion of enhancement intensity, internal perfusion defect and clear boundary after enhancement in the group A was higher than that in the group B and the group C (P<0.05).The above indexes in group B were higher than those in group C (P<0.05). 【Conclusion】The multimodal ultrasound features of patients with HER-2 positive breast cancer are closely related to the expression of ER and PR.
姬利萍, 邢国臣, 冯培贝, 赵玲, 易善永. 雌激素受体、孕激素受体不同表达状态的HER-2阳性乳腺癌患者多模态超声特征分析[J]. 医学临床研究, 2025, 42(3): 433-436.
JI Liping, XING Guochen, FENG Peibei, et al. Multimodal Ultrasonographic Analysis of HER-2 Positive Breast Cancer Patients with Different Expression States of Estrogen Receptor and Progesterone Receptor. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 433-436.
[1] BURSTEIN H J, SOMERFIELD M R, BARTON D L,et al.Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update[J].J Clin Oncol,2021,39(35):3959-3977. [2] WANG C, CHE Y. A ultrasonic nomogram of quantitative parameters for diagnosing breast cancer[J].Sci Rep,2023,13(1):12340. [3] SHAO Y, HASHEMI H S, GORDON P, et al. Breast cancer detection using multimodal time series features from ultrasound shear wave absolute vibro-elastography[J].IEEE J Biomed Health Inform,2022,26(2):704-714. [4] 中国抗癌协会乳腺癌专业委员会. 中国乳腺癌筛查与早期诊断指南[J].中国癌症杂志,2022,32(4):363-372. [5] NICOLO E, TARANTINO P, CURIGLIANO G. Biology and treatment of HER2-low breast cancer[J].Hematol Oncol Clin North Am,2023,37(1):117-132. [6] 岳瑞雪,胡崇珠,郝鑫,等. 曲妥珠单抗和帕妥珠单抗联合不同化疗方案新辅助治疗HER-2阳性乳腺癌真实世界疗效及安全性观察[J].中国肿瘤临床,2023,50(5):248-254. [7] ZHU J Y, HE H L, JIANG X C, et al. Multimodal ultrasound features of breast cancers: correlation with molecular subtypes[J].BMC Med Imaging,2023,23(1):57. [8] WU Q, ZHAN Y, WU J F. Multimodal ultrasound features of sclerosing adenosis of the breast: a case report[J].Med Ultrason,2022,24(4):511-512. [9] ZHANG T Y, TAN T, HAN L Y, et al. Predicting breast cancer types on and beyond molecular level in a multi-modal fashion[J].NPJ Breast Cancer,2023,9(1):16. [10] WU L Y, ZHAO Y J, LIN P, et al. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ[J].BMC Med Imaging,2021,21(1):84. [11] 黄贵廉,陈智毅. 乳腺癌超声征象与分子标志物的相关性研究进展[J].中国医学影像学杂志,2021,29(1):86-88. [12] 冯建丽,马蓉,杨洋,等. 乳腺浸润性导管癌BI-RADS分级与雌激素受体、孕激素受体及人表皮生长因子受体表达的关系[J].海南医学,2021,32(24):3134-3137. [13] 林子梅,孙杨,高云霞,等. 超声造影定性及定量特征与乳腺癌分子标志物表达的相关性研究[J].中华超声影像学杂志,2021,30(7):569-574.
2025, Vol. 42 
